Federation Des Caisses Desjardins Du Quebec Cel Sci Corp Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Aug 30, 2024	SELL	$11.69 - $14.54 $11,690 - $14,540	-1,000 Closed	0 $0
Q4 2019 Aug 30, 2024	BUY	$6.71 - $9.55 $6,710 - $9,550	1,000 New	1,000 $9.15 Million
Q3 2019 Aug 30, 2024	SELL	$6.0 - $9.6 $204 - $326	-34 Closed	0 $0
Q4 2018 Aug 30, 2024	BUY	$2.65 - $4.26 $90 - $144	34 New	34 $98,000
Q2 2017 Aug 30, 2024	BUY	N/A	34	34 $76,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account